🔗 Share this article

Given that the United States undertakes historic revisions to its vaccination recommendations, one figure has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who first made her name by expressing skepticism about Covid shots throughout the pandemic and has zeroed in on alleged fatalities following Covid vaccination in her recent tenure at the FDA.

Scheduled Changes to Childhood Immunization Program

Public health authorities had intended to announce radical revisions to the childhood vaccination calendar earlier this month, aligning the US with the Danish vaccine program, it is understood – a major change that would place the US out of alignment with a large portion of the world with insufficient data for benefit. The announcement has been delayed until the new year.

Instead of Vinay Prasad, Høeg is set to address the audience at the gathering. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the division this year.

Consolidating Power at the FDA

The acting appointment could signify a strengthened alliance between the pharmaceutical and biologics centers as Høeg and Prasad strengthen their influence at the FDA – and it points to a greater focus upon dismantling already-approved immunizations at the FDA.

Høeg has often pushed for ending specific pediatric shot schedules in the US to become more similar to the Danish model, a society with comprehensive healthcare and a population roughly the size of the state of Wisconsin.

So far comments, she has kept her attention on immunizations – typically the purview of Prasad, head of the FDA’s vaccine center – rather than medication approval.

Questions Over Expertise

The appointee has little discernible experience in pharmaceutical research, oversight or leadership, which has been standard for previous heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the commissioner and the vaccine center since spring.

“It seems she lacks to have the requisite experience” for leading the pharmaceutical oversight division, said Dr. Jonathan Howard. “She’s never run a clinical trial. She lacks experience in leading a sizeable institution. She lacks background in industry regulation.”

Past commissioners of CBER would “be deeply familiar with legal statutes and the science of pharmaceutical innovation”, said Dr. Janet Woodcock. “Clearly, she lacks the type of experience that prior appointees who ran CBER have had.”

The drug center has an enormous workload at the FDA, Woodcock stated.

“Everybody just zeroes in on the new drug program, but the off-patent medication office clears thousands of off-brand pharmaceuticals. There’s a biosimilars division, over-the-counter program and so forth, and each of these must be managed,” Woodcock noted. “The responsibility you neglect, that is precisely what that I always told people is going to cause problems.”

Additionally, a substantial leadership component to the position, which oversees over 5,000 personnel. “It is a huge management job, if you execute it properly,” the former official said.

Official Statement and Contentious Initiatives

In response to inquiries about Dr. Høeg's fitness for the role and whether this assignment indicates greater collaboration among regulatory chiefs on vaccines, a representative stated that the “inquiries are based on incorrect premises”.

“Her resume matches the responsibilities of her position,” the official said, noting the period Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Høeg inherits the commissioner’s controversial fast-track approval initiative, a disputed rapid drug-approval program that reportedly worried her predecessors. “How are these medications being selected for this fast-track system? Who makes the decisions?” Dr. Howard questioned. “There is a lot of secrecy going on at the agency right now.”

In general, he said, “the Food and Drug Administration appears to be shifting towards laxer regulations of all drugs, aside from immunizations.”

Documented History on Vaccines

Concerning immunizations, Dr. Høeg has a more documented, if problematic, history, Howard have noted. She released a research paper using unconfirmed volunteer-provided data to assess the incidence of myocarditis following COVID-19 immunization. She advised the Florida chief medical officer Joseph Ladapo, who was said to have changed statistics to indicate COVID-19 vaccines are pose a greater threat than they are.

Included in her “wish list” for the current federal leadership included changing guidelines for new vaccines and ending “unnecessary” immunizations, she remarked post-election on a audio program. At the FDA, Dr. Høeg has allegedly suggested excluding adolescent males from obtaining Covid vaccinations.

“She is an complete ideologue who starts off with her conclusions and reverse-engineers to accommodate the science in a very deceptive, dishonest manner,” Dr. Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg aligned with other skeptics, {like|